Connect Biopharma Holdings Limited financials
$0.9920−8.15%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q4 '22 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.8M | $169.0K | $0.00 | $16.0K | $48.0K | $0.00 | $698.0K | $1.2M | $24.1M | $0.00 | — | — |
| Gross profit | $2.8M | $169.0K | $0.00 | $16.0K | $48.0K | $0.00 | $698.0K | $1.2M | $24.1M | $0.00 | — | — |
| Gross margin | 100.0% | 100.0% | — | 100.0% | 100.0% | — | 100.0% | 100.0% | 100.0% | — | — | — |
| Operating income | -$17.6M | -$19.6M | -$15.5M | -$17.7M | -$13.4M | -$11.4M | -$9.6M | -$13.8M | $13.6M | -$12.6M | — | — |
| Net income | -$17.3M | -$19.4M | -$15.5M | -$17.1M | -$12.9M | -$10.3M | -$9.3M | -$12.3M | $14.8M | -$8.7M | — | — |
| Net margin | −624.4% | −11478.1% | — | −106887.5% | −26872.9% | — | −1337.0% | −1009.5% | 61.6% | — | — | — |
| Diluted EPS | $-0.27 | $-0.34 | $-0.28 | $-0.31 | $-0.23 | $-0.19 | $-0.17 | $-0.23 | $0.27 | $-0.16 | — | — |
| EBITDA | -$17.4M | -$19.4M | -$15.3M | -$17.5M | -$13.3M | -$11.3M | -$9.5M | -$13.7M | $13.8M | -$12.5M | $0.00 | $0.00 |
| Operating cash flow | -$15.9M | -$16.0M | -$11.3M | -$17.4M | -$12.6M | -$10.0M | -$2.3M | -$13.0M | -$7.7M | -$591.0K | — | — |
| Free cash flow | -$15.9M | -$16.0M | -$11.3M | -$17.4M | -$12.9M | -$10.0M | -$2.6M | -$13.2M | -$8.0M | -$591.0K | — | — |
| Diluted shares | 62.9M | 56.5M | 56.1M | 55.7M | 55.5M | 55.4M | 54.8M | 55.3M | 55.7M | 55.1M | 55.1M | 55.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $27.0M | $46.0M | $38.3M | $37.8M | $40.6M | $47.7M |
| Short-term investments | $4.5M | $0.00 | $6.0M | $16.9M | $31.1M | $36.3M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $43.5M | $60.1M | $56.1M | $67.4M | $82.7M | $92.7M |
| Total liabilities | $16.6M | $17.4M | $14.1M | $12.0M | $11.4M | $9.8M |
| Shareholders' equity | $26.9M | $42.6M | $42.0M | $55.4M | $71.3M | $82.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology